Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1993-11-30
1995-09-19
Ivy, C. Warren
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
546 82, 546 83, C07D49804, A61K 3142, A61K 3147
Patent
active
054515858
ABSTRACT:
This invention encompasses compounds of the formula: ##STR1## and the pharmaceutically acceptable non-toxic salts thereof wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4, and W are variables. These compounds are highly selective agonists, antagonists or inverse agonists for GABAa brain receptors or prodrugs thereof and are useful in the diagnosis and treatment of anxiety, sleep, and seizure disorders, overdose with benzodiazepine drugs, and enhancement of memory.
REFERENCES:
patent: 4312870 (1982-01-01), Tokoyama
patent: 4713383 (1987-12-01), Francis et al.
patent: 5182290 (1993-01-01), Albaugh
Merchant and Shirali, Bull. Chem. Soc. of Japan 50: 3075 (1977), "A Simple Method for the Synthesis of 5-Methyloxazolo-[4,5-c]quinolin-4(5H)-ones".
Ivy C. Warren
M. Mach D. Margaret
Neurogen Corporation
LandOfFree
Certain oxazoloquinolinones; a new class of GABA brain receptor does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Certain oxazoloquinolinones; a new class of GABA brain receptor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Certain oxazoloquinolinones; a new class of GABA brain receptor will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1828294